Novo Nordisk

Our discussion guide for Glanzmann’s thrombasthenia can help.

Important Safety Information

Prescribing Information

Novoseven^® RT is uesd to treat bleeding episodes in people with hemophilia A or B with inhibitors, congenial Factor VII deficiency, Glanzmann’s thrombasthenia with resistance to platelets, and acquired hemophilia.

Your experience is
key when talking to your doctor.

Our doctor discussion guide can help you talk about bleeds and the right treatments for Glanzmann's thrombasthenia (GT) with your health care team. If you didn't already take the quiz, start by answering a few true or false statements before you download the guide.

Get Started

Selected Important Safety Information

What is the most important information I should know about NovoSeven^® RT?

NovoSeven^® RT may cause serious side effects, including:

•

Serious blood clots that form in veins and arteries with the use of NovoSeven^® RT have been reported

•

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function

•

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven^® RT

Please click here or scroll below for additional Important Safety Information.

Ask your doctor about the benefits of NovoSeven^® RT

If platelets don't work for you, NovoSeven^® RT may be right for treating your GT-related bleeds.

Fast and effective bleed control for bleeding episodes and surgery

Quick to mix
with a prefilled
syringe

Established
safety profile that
comes from
years of experience

Educational support for your journey with Glanzmann’s thrombasthenia.

Our local representatives–aka Hemophilia Community Liaisons (HCLs)–are ready to provide resouces and information on rare bleeding disorders.
Connect with your local HCL for 1-on-1 support.

What is NovoSeven^® RT?

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

•

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions

•

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information (cont’d)

•

You should not use NovoSeven^® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven^® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven^® RT?

•

Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:

	◦	congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
	◦	are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
	◦	history of heart or blood vessel diseases

•

Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven^® RT?

•

The most common and serious side effects are blood clots

•

Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please do not respond to this email. If you would like to contact us, please click here or call 1-877-744-2579.

UNSUBSCRIBE NOTICE

If you no longer want to receive communications from Novo Nordisk, the sponsor of this content, click here to unsubscribe. You also may call Novo Nordisk at 1.877.744.2579 or send a letter that includes your full contact information (e.g. name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see the Privacy Statement.